Marquette Asset Management LLC grew its position in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) by 7.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 38,000 shares of the company’s stock after purchasing an additional 2,500 shares during the quarter. Marquette Asset Management LLC owned 0.07% of Chinook Therapeutics worth $665,000 as of its most recent filing with the SEC.
Several other hedge funds also recently modified their holdings of the company. Amalgamated Bank acquired a new position in shares of Chinook Therapeutics during the 1st quarter valued at $77,000. International Biotechnology Trust PLC increased its position in shares of Chinook Therapeutics by 17.6% during the 1st quarter. International Biotechnology Trust PLC now owns 340,389 shares of the company’s stock valued at $4,714,000 after purchasing an additional 51,000 shares during the period. Great Point Partners LLC increased its position in shares of Chinook Therapeutics by 265.0% during the 1st quarter. Great Point Partners LLC now owns 1,423,682 shares of the company’s stock valued at $23,291,000 after purchasing an additional 1,033,641 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Chinook Therapeutics by 7.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 234,738 shares of the company’s stock worth $3,841,000 after acquiring an additional 16,512 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Chinook Therapeutics in the 1st quarter worth $760,000.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on KDNY. Stifel Nicolaus began coverage on Chinook Therapeutics in a report on Monday, June 27th. They issued a “buy” rating and a $30.00 target price on the stock. HC Wainwright lifted their target price on Chinook Therapeutics from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, August 15th.
Insider Transactions at Chinook Therapeutics
Chinook Therapeutics Stock Performance
Shares of Chinook Therapeutics stock traded down $0.67 during midday trading on Friday, hitting $18.99. The company’s stock had a trading volume of 577,271 shares, compared to its average volume of 515,776. The stock has a 50-day simple moving average of $20.48 and a 200-day simple moving average of $17.39. Chinook Therapeutics, Inc. has a 1-year low of $10.48 and a 1-year high of $23.86.
Chinook Therapeutics (NASDAQ:KDNY – Get Rating) last issued its earnings results on Monday, August 8th. The company reported ($0.61) EPS for the quarter, hitting the consensus estimate of ($0.61). Chinook Therapeutics had a negative return on equity of 22.18% and a negative net margin of 170.15%. On average, sell-side analysts anticipate that Chinook Therapeutics, Inc. will post -2.47 EPS for the current fiscal year.
About Chinook Therapeutics
Chinook Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.
- Get a free copy of the StockNews.com research report on Chinook Therapeutics (KDNY)
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Chinook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chinook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.